Hyaluronidase And Rituximab

Introduction Overview

Generic Name

hyaluronidase and rituximab

Brand Name

Rituxan Hycela

Dosage Form

Subcutaneous injection (single-dose vial)

Drug Class

CD20 monoclonal antibodies

Pharmacokinetics

Rituxan Hycela is a fixed-dose combination of rituximab, a chimeric monoclonal antibody targeting the CD20 antigen on B cells, and recombinant human hyaluronidase, an enzyme that transiently degrades hyaluronan in the subcutaneous tissue to facilitate dispersion and absorption.

Absorption:
Following subcutaneous administration, the bioavailability of rituximab is increased by hyaluronidase, which temporarily breaks down the extracellular matrix allowing larger volumes to be absorbed. Clinical data suggest rituximab achieves therapeutic serum concentrations comparable to intravenous administration following the initial IV dose. The subcutaneous route results in slower absorption than IV infusion, with peak serum concentrations attained later, typically several days after injection, yet effective for sustained B-cell depletion. The hyaluronidase component enhances local tissue permeability, significantly improving the absorption kinetics of rituximab from the subcutaneous depot.

Distribution:
Rituximab distributes primarily in the vascular and interstitial compartments, binding to CD20-positive B lymphocytes. The volume of distribution is relatively restricted, consistent with monoclonal antibodies. Binding to CD20 antigens on B cells in lymphoid tissues and circulation contributes to its pharmacodynamic effect. Hyaluronidase acts locally to modify subcutaneous tissue matrix but does not significantly alter systemic distribution of rituximab. The distribution to malignant lymphoid tissues enables targeted depletion of pathological B-cell populations.

Metabolism:
Rituximab metabolism occurs through catabolic degradation pathways typical of IgG monoclonal antibodies, primarily via reticuloendothelial system and lysosomal proteolysis in target and non-target cells. The catabolism yields small peptides and amino acids that are reused or eliminated. Hyaluronidase is a recombinant enzyme that undergoes rapid systemic degradation and inactivation after fulfilling its local action on the subcutaneous matrix. Neither rituximab nor hyaluronidase undergoes hepatic metabolism via cytochrome P450 enzymes.

Elimination:
The elimination half-life of rituximab following subcutaneous administration is generally consistent with its intravenous counterpart, ranging from approximately 18 to 22 days, though variability occurs based on disease state and individual factors. Clearance primarily occurs via target-mediated elimination after binding CD20 on B-cells and nonspecific proteolytic catabolism. Hyaluronidase is rapidly eliminated from local tissues and systemic circulation within hours post-dose, primarily via proteolytic degradation. Due to the prolonged half-life of rituximab, treatment intervals are spaced typically every 21 to 28 days or longer depending on regimen indication, supported by its sustained B-cell depletion.

Dosage Forms

Available Dosage Forms:
Rituxan Hycela is supplied as a subcutaneous single-dose vial combining rituximab and hyaluronidase human. The two main strengths include:
- 1,400 mg rituximab and 23,400 units hyaluronidase per 11.7 mL vial (120 mg/mL rituximab, 2,000 units/mL hyaluronidase)
- 1,600 mg rituximab and 26,800 units hyaluronidase per 13.4 mL vial (120 mg/mL rituximab, 2,000 units/mL hyaluronidase)

Dosages for Adults and Adolescents:
Rituxan Hycela dosing must always be preceded by at least one full intravenous dose of rituximab to verify tolerance. Following this, subcutaneous dosing regimens vary by indication:
- Follicular lymphoma (relapsed/refractory): 23,400 units hyaluronidase and 1,400 mg rituximab subcutaneously once weekly for 3 or 7 weeks.
- Follicular lymphoma (previously untreated): 1,400 mg rituximab plus 23,400 units hyaluronidase subcutaneously on Day 1 of chemotherapy cycles 2-8 every 21 days; with single-agent maintenance every 8 weeks for up to 12 doses.
- Diffuse large B-cell lymphoma: 1,400 mg rituximab and 23,400 units hyaluronidase subcutaneously on Day 1 of cycles 2 through 8 of CHOP chemotherapy.
- Chronic lymphocytic leukemia: 1,600 mg rituximab and 26,800 units hyaluronidase on Day 1 of cycles 2 through 6 every 28 days following initial IV rituximab dose.

Specific Patient Populations:
Treatment requires careful monitoring in patients with history of hepatitis B virus due to risk of reactivation. Pregnancy and breastfeeding are contraindicated. Elderly patients tolerate Rituxan Hycela similarly to general adult population but require vigilance for infections and cytopenias. Patients with renal or hepatic impairment require clinical monitoring but specific dose adjustments have not been established. Immunocompromised patients require monitoring for infection and immune reconstitution. Premedication with acetaminophen, antihistamines, and consideration of glucocorticoid administration is recommended before every dose.

Administration Method:
Rituxan Hycela is given by subcutaneous injection in the abdominal area, over 5 to 7 minutes, by healthcare providers due to potential for infusion-related reactions. Patients are observed post-administration for at least 15 minutes for signs of hypersensitivity.

Clinical Guidelines:
Use of Rituxan Hycela should follow established oncology protocols and treatment guidelines for lymphomas and chronic lymphocytic leukemia, including appropriate pre-treatment with IV rituximab, premedication, infection monitoring, and avoidance of live vaccines during and for months after treatment.

Mechanism Of Action

Rituxan Hycela combines rituximab, a chimeric monoclonal antibody targeting the CD20 antigen expressed on pre-B and mature B lymphocytes, with hyaluronidase, an enzyme that facilitates subcutaneous absorption.

Rituximab binds selectively to the CD20 protein present on the surface of malignant and normal B cells. This binding initiates multiple mechanisms leading to B-cell depletion, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and direct induction of apoptosis. The binding disrupts B-cell survival signals and triggers immune effector mechanisms resulting in elimination of pathological B cells, which play a pivotal role in lymphoma and leukemia pathogenesis.

The clearance of CD20-positive B cells dampens the abnormal proliferation of these malignant cells in diseases such as follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. This targeted immunotherapy spares plasma cells and hematopoietic stem cells, preserving long-term immune function.

Hyaluronidase facilitates the dispersion and absorption of the rituximab antibody by transiently depolymerizing hyaluronic acid, a key component of the extracellular matrix in subcutaneous tissue. This enzymatic action temporarily increases tissue permeability, allowing high volumes of rituximab to be administered via subcutaneous injection efficiently with pharmacokinetic profiles comparable to intravenous dosing. The combination improves patient convenience and reduces administration time while maintaining therapeutic efficacy.

Clinical studies demonstrate that subcutaneous Rituxan Hycela offers non-inferior efficacy and safety compared with intravenous rituximab, including comparable B-cell depletion, progression-free survival, and overall response rates. The subcutaneous formulation thus represents an advancement by improving patient comfort without compromising the antibody's established molecular mechanisms of action.

Pharmacological Actions

Selective targeting and binding to CD20 antigen on B lymphocytes.
Induction of complement-dependent cytotoxicity leading to B-cell lysis.
Mediation of antibody-dependent cellular cytotoxicity via immune effector cells.
Promotion of direct apoptosis in malignant B cells.
Transient enzymatic degradation of hyaluronic acid to facilitate subcutaneous absorption.
Reduction of malignant B-cell burden in various lymphoproliferative diseases.
Preservation of humoral immunity by sparing plasma cells and progenitors.
Synergistic effect with chemotherapy agents in combination regimens.
Immune system modulation resulting in prolonged B-cell depletion.
Increased bioavailability and patient compliance through subcutaneous administration.
Rapid local absorption due to hyaluronidase enhancing local tissue permeability.
Pharmacodynamic effect measured by peripheral B-cell count reduction.
Long elimination half-life enabling spaced dosing intervals.
Potential to cause immunosuppression and increased infection risk due to B-cell depletion.
Utility as both induction and maintenance therapy in follicular lymphoma.

Therapeutic Or Clinical Uses

Treatment of relapsed or refractory follicular lymphoma as a single agent.
Treatment of previously untreated follicular lymphoma in combination with first-line chemotherapy.
Maintenance therapy in follicular lymphoma following response to induction chemotherapy.
Treatment of non-progressing follicular lymphoma post first-line CVP chemotherapy.
Treatment of previously untreated diffuse large B-cell lymphoma (DLBCL) in combination with CHOP chemotherapy.
Treatment of chronic lymphocytic leukemia (CLL) in combination with fludarabine and cyclophosphamide.
Use in patients after initial intravenous rituximab dose to facilitate subcutaneous administration.
Alternative to intravenous rituximab to improve patient comfort and reduce infusion times.
Depletion of malignant B-cells in lymphoproliferative disorders.
Potential adjunct therapy for other CD20-positive B-cell malignancies under investigation.
Facilitation of outpatient treatment regimens for lymphoma and leukemia.
Reduction of disease burden via targeted immunotherapy in hematological cancers.
Combination use with anthracycline-based chemotherapy regimens.
Used in disease management protocols that require prolonged maintenance therapy.
Treatment strategy to minimize infusion reactions by prior intravenous dose.

Side Or Adverse Effects

Injection site reactions including redness and discomfort.
Low blood cell counts (including neutropenia, anemia, and thrombocytopenia) increasing infection and bleeding risk.
Nausea, vomiting, and constipation.
Hair loss (alopecia) commonly seen with combination chemotherapy.
Fatigue and general malaise.
Cough and respiratory symptoms.
Hypersensitivity reactions ranging from mild rash to severe anaphylaxis.
Infusion-related reactions such as fever, chills, itching, dizziness, shortness of breath.
Serious infections including opportunistic infections and reactivation of hepatitis B virus.
Progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain infection.
Severe skin reactions including painful sores, blistering, peeling, and rash.
Cardiac arrhythmias and chest pain in susceptible individuals.
Tumor lysis syndrome characterized by metabolic disturbances and acute renal failure.
Headache and neurological symptoms including confusion or seizures.
Potential fetal harm; contraindicated in pregnancy.

Precautions

Premedicate with acetaminophen and antihistamines before each dose to reduce infusion reactions.
Consider glucocorticoid premedication depending on regimen and patient history.
Monitor blood counts regularly due to risk of cytopenias.
Closely observe patients during and after injection for allergic reactions.
Avoid live vaccines during treatment and for months afterward due to immune suppression.
Screen patients for hepatitis B virus infection before initiating therapy and monitor during treatment.
Exercise caution in patients with cardiac disease or arrhythmias.
Use effective contraception during treatment and for at least 12 months after last dose.
Do not breastfeed during therapy and for at least 6 months post-treatment.
Monitor liver function tests regularly, especially in patients with past hepatitis infection.
Evaluate immune status and infection history prior to initiation.
Adjust therapy with consideration to concurrent chemotherapy or immunosuppressive agents.
Be vigilant for signs of tumor lysis syndrome and manage proactively.
Use cautiously in patients with compromised renal or pulmonary function.
Educate patients on symptoms of infection and adverse effects requiring immediate medical attention.

Warnings

Do not use during pregnancy due to potential for fetal harm; women must avoid pregnancy for 12 months post-therapy.
Serious and sometimes fatal brain infections (PML) have occurred; monitor neurological status carefully.
Risk of hepatitis B virus reactivation which can be severe or fatal.
Severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported.
Infusion-related reactions may occur during or within 24 hours of injection; immediate medical attention is required if symptoms develop.
Increased susceptibility to serious infections; monitor for fever, sore throat, and other infection signs.
Potential for severe allergic reactions; have resuscitation equipment and emergency medications available during administration.
Avoid live vaccines during treatment and for several months after due to immunosuppression.
Use caution in patients with pre-existing cardiac conditions; arrhythmias and chest pain can occur.
The drug may cause prolonged B-cell depletion leading to delayed immune recovery.
Risk of tumor lysis syndrome particularly in patients with high tumor burden.
Risk of cytopenias that may cause serious bleeding or infection complications.
Patients should be monitored for delayed adverse reactions that can occur months after treatment.
Discontinue drug if severe hypersensitivity or anaphylaxis occurs.
Patients should be educated to report neurologic symptoms immediately.

Contraindication

Known hypersensitivity to rituximab, hyaluronidase, or any component of the formulation.
Active severe infections until adequately treated.
Pregnancy due to teratogenic potential and fetal harm.
Breastfeeding mothers during treatment and for at least 6 months post-therapy.
Patients with a history of severe allergic reactions to monoclonal antibodies.
Use in patients with significant immunodeficiency disorders without careful risk evaluation.
Concurrent administration with live vaccines due to risk of inadequate immune response or vaccine-derived infection.
Severe uncontrolled cardiac disease where adverse cardiac effects may be exacerbated.
Severe skin conditions or active dermatologic diseases that may worsen with therapy.
Patients with a history of progressive multifocal leukoencephalopathy (PML).
Use in pediatric patients has not been established; contraindicated outside approved indications.

Drug Interactions

May potentiate immunosuppressive effects when used with other chemotherapeutic or immunosuppressive agents.
Concurrent use with live vaccines is contraindicated due to impaired vaccine efficacy and risk of infection.
Potential interaction with concomitant medications that lower white blood cell counts, increasing infection risk.
No direct cytochrome P450 metabolism; low potential for pharmacokinetic interactions.
Drugs that alter immune function may exacerbate immunosuppression when combined.
Concurrent use with agents causing cardiac arrhythmias requires monitoring.
Medications that modulate cytokine activity may influence infusion reactions.
Corticosteroids used as premedication for Rituxan Hycela may interact with other drugs affecting adrenal function.
Use with anticoagulants requires caution due to potential bleeding from thrombocytopenia.
Administration with drugs causing tumor lysis syndrome requires careful metabolic monitoring.
Avoid combinations with nephrotoxic agents in patients at risk of renal impairment.
Immunomodulatory agents may impact therapeutic response or adverse effect profile.
Potential additive myelosuppression when combined with other cytotoxic drugs.
Regular assessment recommended when coadministered with antiviral agents especially in hepatitis B patients.
Herbal supplements with immunomodulatory effects should be used cautiously.

Preparations Of The Drug

Single-dose vial containing 1,400 mg rituximab and 23,400 units hyaluronidase per 11.7 mL (120 mg/mL rituximab; 2,000 units/mL hyaluronidase).
Single-dose vial containing 1,600 mg rituximab and 26,800 units hyaluronidase per 13.4 mL (120 mg/mL rituximab; 2,000 units/mL hyaluronidase).
Supplied as a preservative-free ready-to-use solution for subcutaneous injection.
Stored refrigerated; protected from light and used within specified time post-reconstitution.
Provided with clear instructions for slow subcutaneous administration over 5 to 7 minutes.
Prefilled syringes or infusion bags are not commercially available; administration by trained healthcare professionals only.
Packaged with appropriate labeling highlighting contraindications and administration precautions.
Used exclusively for subcutaneous administration following initial intravenous rituximab dose.
No need for further dilution; supplied in concentrations designed for fixed-dose administration.
Each preparation batch undergoes stringent quality control to assure purity and biologic activity.
Packaging includes patient information leaflets specifying safety monitoring requirements.
Compatible with standard subcutaneous injection devices and techniques as per clinical protocols.
Available through specialty pharmacies and oncologic treatment centers.
Preparation guidelines emphasize aseptic technique to prevent contamination.
Disposal recommendations comply with biomedical waste regulations for monoclonal antibody products.